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BACKGROUND. Despite clinical associations and in vitro data suggesting that autocrine
interleukin-6 (IL-6) production contributes to prostate cancer progression or chemotherapy
resistance, there have been no reports that explore the role of IL-6 on prostate tumors in vivo.
In the present study, we investigated the effect of IL-6 inhibition on the growth of human
prostate cancer xenografts in nude mice.
METHODS. To determine if autocrine IL-6 production contributes to prostate cancer growth
and chemotherapy resistance in vivo, xenografts of a human prostate cancer cell line that
produces IL-6 (PC-3) were established in nude mice. The mice were randomly divided
into four treatment groups: (1) saline (vehicle control)murine IgG (isotype control); (2)
etoposidemurine IgG; (3) saline anti-IL-6 monoclonal antibody; and (4) etoposide anti-
IL-6 monoclonal antibody. Tumors were measured twice weekly during a 4-week treatment
period. At the conclusion of the study, all mice were sacri®ced, and in addition to ®nal volume,
tumors were evaluated for the degree of apoptosis by TUNEL analysis.
RESULTS. Anti-IL-6 Ab (with saline or etoposide) induced tumor apoptosis and regression
(60% compared to initial tumor size). Etoposide alone did not induce tumor regression or
apoptosis in this animal model, and there was no synergy between anti-IL-6 Ab and etoposide.
CONCLUSIONS. These studies suggest that IL-6 contributes to prostate cancer growth in
vivo, and that targeting IL-6 may contribute to prostate cancer therapy. Prostate 48:47±53, 2001
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INTRODUCTION
Prostate cancer is the most common cancer diag-
nosed in men and the second leading cause of cancer
death among men in the United States. In 1999, it was
estimated that 179,300 patients were diagnosed with
prostate cancer, and 37,000 patients died from the
disease [1]. Radical prostatectomy can be curative in
patients with localized prostate cancer. Unfortunately,
many patients have an advanced form of the disease at
the time of diagnosis, and require systemic androgen-
ablation therapy. Initially the cancer appears as an
androgen-sensitive phenotype and is responsive to
this treatment. However, after a median time of 12±18
months, it commonly recurs as a hormone-refractory
phenotype that is also resistant to other therapeutic
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modalities including chemotherapy [2]. The precise
mechanism of drug resistance in prostate cancer is not
fully understood, but the secretion of protective facto-
rs by these tumors may play a role.
The cytokine interleukin-6 (IL-6) has been impli-
cated in a number of pathophysiologic processes
including stimulation of tumor proliferation [3]. In
the past few years, evidence has been accumulating
that IL-6 may contribute to the progression of prostate
cancer [4]. For example, IL-6 serum levels are
correlated with morbidity and tumor burden of
prostate cancer patients [5]. Furthermore, the addi-
tion of anti-IL-6 antibody to the growth medium of
androgen-independent prostate cancer cell lines has
been shown to inhibit cell growth [6,7]. Additionally,
inhibition of IL-6 activity enhances the cytotoxic
activity of certain chemotherapeutic agents in prostate
cancer cell lines that are resistant to the drugs [8]. In
spite of the many studies demonstrating that IL-6
promotes prostate cancer proliferation and survival in
cell culture, there has been no in vivo evidence to
con®rm that IL-6 contributes to prostate cancer
growth. Accordingly, to determine if IL-6 contributes
to prostate cancer progression, we examined the effect
of inhibiting IL-6 activity on prostate cancer progres-




The hormone-independent prostatic carcinoma
cell lines PC-3 and DU145, and the hormone-depen-
dent cell line, LNCaP (ATCC) were cultured in
complete medium (RPMI 1640 with L-glutamine
supplemented with 10% heat-inactivated fetal bovine
serum, and 1% penicillin/streptomycin solution con-
taining 10,000 units/ml penicillin G and 10,000 mg/ml
streptomycin). All three cell lines were grown in a
humidi®ed incubator at 37C in 5% CO2. Cells were
treated with trypsin-EDTA, washed, and resuspended
in complete medium prior to their use in cytotoxicity
assays.
Antibodies
Anti-hIL-6 (CLB, Amsterdam, The Netherlands) an-
tibody is a mouse monoclonal (subtype IgG1) speci®c
for human IL-6 [9]. Mouse IgG1k (Sigma, St. Louis,
MO) was used as an isotype control antibody.
Etopsoide
Etoposide (Sigma) was dissolved in 1 ml DMSO to a
®nal stock concentration of 25 mg/ml and stored at
4C. The stock solution was diluted to the indicated
concentrations in complete medium (in vitro experi-
ments) or normal saline (in vivo experiments) imme-
diately prior to use.
IL-6Measurements inCell Culture
Cells were grown in 10-cm polystyrene tissue cul-
ture dishes. Con¯uent cells were washed once with
phosphate-buffered saline and then incubated for 48-
hr in complete medium, at which time the supernatant
was collected and stored at ÿ 20C until assayed.
IL-6 concentration was measured using a commercial
ELISA kit (Quantikine Human IL-6 ELISA Kit; R&D,
Systems Inc., Minneapolis, MN) as directed by the
manufacturer.
In some cases, IL-6 levels were measured following
the addition of anti-IL6 antibody. In these instances,
cells were plated in 6-well polystyrene tissue culture
plates at a density of 5 105/well in 2.5-ml complete
medium. Anti-IL6 monoclonal antibody, isotype con-
trol (®nal concentration of 500 ng/ml), or complete
medium was added to appropriate wells and cells
were incubated at 37C. Supernatant samples were
collected from each well at 24, 48, and 72 hr and stored
at ÿ 20C until ELISA was performed.
Serum IL-6 Levels
At the time of sacri®ce, blood samples were colle-
cted via cardiac puncture and centrifuged at 2,700 rpm
for 10 min. The serum was removed from each sample
and stored at ÿ 80C until assayed for IL-6 using the
B9 cell IL-6 bioassay as previously described [10].
InVitroCytotoxicity Experiments
Cell lines were seeded in 96-well plates at a density
of 2 103 cell/well in 100-ml complete medium. Either
anti-IL6 or isotype control antibody was added at a
concentration of 2 mg/ml (®nal concentration to be 500
ng/ml) in 50 ml of complete medium, and etoposide
was added in a 50-ml/volume to reach a ®nal concen-
tration of 0.1 or 10 mg/ml (approximate ID25 and ID50,
respectively; data not shown). Saline vehicle was
added to cells that did not receive etoposide. The cells
were then incubated for 48 hr. Cell viability was then
determined using an MTS assay (Promega, Madison,
WI) as directed by the manufacturer. Cytotoxicity was
calculated as follows:





Eight-week-old nude (nu/nu) mice (Charles River
Laboratories, Wilmington, MA) were kept in a speci®c
pathogen free colony, in microisolator cages, and were
fed sterile rodent chow and sterile water ad libitum.
All protocols were approved by the University of
Michigan Animal Care and Use Committee.
InVivo Experiments
Con¯uent PC-3 cells were harvested by trypsinza-
tion, washed twice with PBS and resuspended at a
density of 1 107 cells/ml. The mice were injected
subcutaneously with 100 ml of the tumor cell suspen-
sion (106 cells) combined with 100 ml of Matrige
1
(Bectin-Dickson, Bedford, MA). The mice were mon-
itored for tumor growth, and when tumors were
detected by palpation, measurement of the tumors
began. Tumor volumes were calculated by the formu-
la: Volume [(minimum measurement)2 (maximum
measurement)] 72 [as described in Ref. [11]]. Tumors
were measured every other day, and when tumors
reached a volume of 126 mm3 the mice were randomly
assigned to one of four treatment groups (n 10/
group). Treatment groups included isotype saline,
isotype etoposide, anti-IL-6 saline, and anti-IL-6
etoposide. The treatment regimen consisted of weekly
i.p. injection of anti-IL6 or isotype antibody at 500 mg/
mouse/week as previously described [12] and daily
i.p. injections of etoposide at 50 mg/m2/day, which is
the human-equivalent dose [13], or an equal volume of
saline. Mouse IL-6 does not react with human IL-6
receptor [14]. Thus, using an anti-human-IL-6 alone
will inhibit the IL-6 speci®cally produced by the hu-
man prostate cancer cells. Treatment continued for 4
weeks, during which time the tumors were measured
on a twice-weekly basis. At the conclusion of the study
all mice were sacri®ced, and blood and tissue samples
were collected for further analysis.
TumorHistopathology andDetection of Apoptosis
Excised tumors were placed in 10% formalin,
embedded in paraf®n and sectioned at 10 mM thick-
ness. Sections were examined utilizing standard
hematoxylin and eosin (H&E) staining for routine
histopathology. To evaluate apoptosis, sections were
deparaf®nized, rehydrated, and subjected to terminal
deoxytransferase UTP end-labeling (TUNEL) analysis
using ApopTag
1
Plus Peroxidase Kit (Intergen, Pur-
chase, NY) according to the manufacturer's directions.
The number of apoptotic nuclei per 200X ®eld (aver-
aged from three random 200X ®elds) was determined
for each section by an investigator that was blinded to
the samples as previously described [15].
Statistical Analysis
To determine differences among treatment groups
for tumor size, two-way analysis of variance (ANO-
VA) was used followed by Fisher's least signi®cant di-
fference for post-hoc analysis. Statistical signi®cance
was determined at P<0.05.
RESULTS
IL-6 Secretionby ProstateCancer Cell Lines
The detection of IL-6 secretion by prostate cancer
cell lines is fairly inconsistent between laboratories
[6,7,16]. Thus, it was critical to determine the IL-6
expression of various cell lines in our laboratory prior
to proceeding with an in vivo challenge. Accordingly,
we measured the amount of IL-6 secreted into the
culture supernatant of various prostate cancer cell
lines. PC-3 cells secreted the most IL-6 followed by
DU-145 cells (Fig. 1A). IL-6 was undetectable in
LNCaP cell culture supernatant (Fig. 1A).
Effectof IL-6AntibodyTreatmenton IL-6 Levels in
PC-3 Cell Culture Supernatant
In order to provide a maximum challenge to our
ability to inhibit IL-6, we performed the remaining
experiments with the PC-3 cells, which secreted the
highest levels of IL-6. To con®rm that the anti-IL-6
antibody we were using effectively inhibited IL-6 leve-
ls over a length of time, we incubated PC-3 cells with
500 ng/ml of either anti-IL-6 or isotype control anti-
body for 24, 48, and 72 hr, then measured IL-6 levels
using ELISA. Anti-IL-6 antibody decreased the detec-
tion of IL-6 by  50% at all three time points compared
to the isotype antibody (Fig. 1B).
EffectofAnti-IL- 6 andEtoposideonCellProliferation
of PC-3 Cells
To determine if anti-IL-6 antibody enhances the
etoposide-mediated cytotoxicity of prostate cancer
cells, we incubated prostate cancer cells with anti-
body and etoposide, then measured viable cell
number. Anti-IL-6 antibody alone decreased the
number of viable cells by approximately 10% (Fig. 2).
Etoposide alone at low (0.1 mM) and high (10 mM)
doses induced approximately 5% cytotoxicity. Anti-
IL-6 antibody combined with the high dose of etopo-
side induced approximately 25% cytotoxicity, thus
demonstrating a synergistic effect between etoposide
and anti-IL-6 antibody in vivo. These in vitro data
provided the rationale to pursue the ability of IL-6
antibody to modulate prostate cancer cell growth
in vivo.
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Tumor Response
Based on our observation that inhibition of IL-6
alone inhibited PC-3 survival in addition to enhan-
cing-mediated cytotoxicity in vivo, we next explored if
inhibiting IL-6 would mimic these effects in vivo on
established prostate cancer tumors. To accomplish
this, PC-3 cells were subcutaneously injected into nude
mice. The tumors were allowed to develop until they
were approximately 126 mm3, at which time anti-IL-6
or isotype antibody and etoposide administration was
initiated. Antibody was administered at a level
that inhibited IL-6 bioactivity by approximately 20%
(based on B9 bioassay; data not shown). Treatment
was continued for a 4-week period. Using an ELISA
speci®c for human IL-6 (and non-cross-reactive with
murine IL-6), we determined that serum human IL-6
levels were 30.1 10.4 pg/ml in tumor-implanted
saline isotype control mice, compared to undetect-
able levels in mice not implanted with tumor, demo-
nstrating that the tumors produced IL-6 in vivo. The
tumors in the isotype-treated mice had a continuous,
albeit slow, tumor growth rate, whereas the tumors in
the istotype etoposide-treated mice did not grow
(Fig. 3). In contrast, the ®nal tumor volumes were redu-
ced by approximately 60% compared to their initial
size in the mice receiving anti-IL-6 or anti-IL6 etopo-
side. Furthermore, they were approximately 75% sma-
ller than the tumors in the mice receiving isotype alone
(Fig. 3). There was no signi®cant difference between
the tumor volumes in the mice treated with istotype
alone compared to the mice treated with etoposide
alone.
Apoptosis
We evaluated the effect of anti-IL-6 antibody and
etoposide on the amount of apoptosis present in
the PC-3 tumors. Routine histological evaluation of the
tumors did not demonstrate any differences among
the treatment groups. However, administration of
anti-IL-6 antibody was associated with marked apop-
Fig. 1. Anti IL-6 antibodydiminished ELISAdetectable IL-6 from
PC-3cells.A:Theindicatedprostate cancercell lineswereplatedat
a density of 5106 cells/10ml in10 cm tissue culture plates and cul-
tured for 48 hr. Supernatant was then collected and subjected to
ELISA for IL-6.B: PC-3 cells were plated in 6-well polystyrene tis-
sue culture plates at a density of 5105/well in 2.5 ml complete
medium. Anti-IL-6 monoclonal antibody or isotype control (final
concentration of 500 ng/ml) was added and cells were incubated at
37C.Supernatant sampleswere collected fromeachwell at 24,48,
and 72 hr and subjected to ELISA for IL-6. All timepointswere run
on the same plate. Both assays were performed in triplicate.
*P<0.01vs.LNCaP, #P<0.01vs.DU-145, }P<0.05 vs. isotype.
Fig. 2. Inhibition of IL-6 induces cytotoxicity of PC-3 cells in
vitro.Cell lineswere seeded in 96-well plates at a density of 2103
cells/well in100ml completemedium.Either anti-IL6or isotype con-
trolantibodywas addedat a concentrationof2mg/ml (final concen-
tration tobe500ng/ml) in50mlofcompletemedium.Etoposidewas
addedin a 50ml/volume toreach a final concentrationof 0.1mg/mlor
10mg/ml (approximate ID25 and ID50, respectively; data not shown).
Saline vehiclewas added towells not receiving etoposide.The cells
were then incubated for 48 hr.Cell viability was then determined
using an MTS assay and cytotoxicity was determined as described
in the Methods section. The assay was performed in triplicate
*P<0.05 vs. isotype.
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tosis in the tumors from both the saline vehicle and
etoposide treated mice, compared to the moderate
level of apoptosis in the tumors from the isotype and
isotype etoposide-treated mice (Fig. 4). These data
demonstrate that IL-6 has an anti-apoptotic action in
PC-3 cells in vivo.
DISCUSSION
A large body of evidence has accumulated that
suggests IL-6 contributes to prostate cancer progres-
sion. The evidence includes both clinical observations
that increased levels of IL-6 are associated with incre-
asing grade of prostate cancer in patients [5,17,18] and
in vitro experiments that have demonstrated that IL-6
promotes prostate cancer cell growth and prevents
chemotherapeutic-mediated cytotoxicity [7,19]. In the
current study, we provide the ®rst demonstration that
IL-6 activity promotes prostate cancer growth in vivo.
Our data demonstrate that high levels of IL-6 are
secreted by PC-3 and DU-145 cells, whereas IL-6 lev-
els were not detectable using ELISA methodology
in LNCaP cells. These ®ndings are consistent with
previous reports on IL-6 secretion by prostate cancer
cell lines [6,8]. PC-3 and DU-145 cells are andro-
gen non-responsive, whereas LNCaP cells are andro-
gen-responsive. Thus, these results suggest that loss of
androgen responsiveness is associated with increased
IL-6 expression. This postulation is consistent with the
observations that elevation of serum IL-6 levels is
associated with increasing grade of prostate cancer
[5,18,20]. A cause and effect cannot be determined
based on the current data. However, it has been previ-
ously reported that the androgen dihydrotestosterone
inhibits IL-6 expression in prostate cancer cells [16]
and that orchiectomy increased IL-6 expression in
murine bone marrow [10]. Thus, it is plausible that loss
of androgen-response promotes IL-6 expression.
Prostate cancer is poorly responsive to chemother-
apy. Therefore, a mechanism to enhance chemother-
apeutic killing of tumors would be a boon for prostate
cancer patients. Borsellino et al. [7] have reported that
inhibition of IL-6 activity enhances chemotherapeutic
killing of prostate cancer cell in vitro. However, this
effect has not been reported in vivo. In the current
study, the cell type and therapeutic agent were chosen
based on in vitro studies, and the human equiva-
lent dose of etoposide was used to calculate the dosage
administered to the mice. However, we did not
observe an effect of etoposide on the PC-3 in vivo. In
contrast, tumors responded to anti-IL-6 antibody,
although the combination of anti-IL-6 and etoposide
did not signi®cantly enhance this inhibitory effect
compared to anti-6 alone. Taken together, these data
suggest that inhibition of IL-6 does not enhance etopo-
side-mediated killing in vivo. However, they clearly
demonstrate that inhibition of IL-6 alone, or in the
presence of etoposide, induces regression of PC-3
tumors. This observation provides in vivo evidence
that IL-6 contributes to prostate cancer cell growth,
and that inhibition of its activity promotes tumor
regression.
This ability to inhibit IL-6 activity in humans has
been previously demonstrated in several clinical
trials using murine monoclonal antibodies in patients
with multiple myeloma [21,22]. Early trials demon-
strated the feasibility of blocking IL-6 activity in this
manner, and that such therapy had bene®cial effects
[21]. These trials also revealed certain limitations to
anti-IL-6 therapy using murine monoclonal antibo-
dies. One such limitation is that in some patients with
advanced disease, IL-6 levels were so high that the
antibody was unable to neutralize them [22]. Another
limitation is that development of antibodies to mouse
immunoglobulin may result in rapid clearance of the
murine monoclonal antibody and diminished ef®cacy
of treatment [23]. This problem has been addressed
through the chimerization [23,24] and humanization
[24] of murine anti-IL-6 antibodies. Tsunenari et al.
[24] demonstrated reduced antigenicity of chimeric
antibodies and even lower antigenicity of humanized
murine antibodies (24) while a later study by van
Zaanen et al. [23] showed no induction of human anti-
chimeric antibodies in multiple myeloma patients
receiving chimeric anti-IL-6 antibodies. Overall, these
studies suggest that inhibition of IL-6 activity in
prostate cancer patients is achievable.
Fig. 3. Inhibition of IL-6 induces PC-3 xenograft regression in
mice. PC-3 cells (106) in a Matrigel slurry were subcutaneously
implanted in male nu/nu mice. When tumors reached 126 cm3,
weekly i.p. injections of anti-IL6 or isotype antibody (500 mg/
mouse) and daily i.p. injections of etoposide (50 mg/m2) or saline
vehicle were initiated.Tumors were measured twice-weekly for 4
weeks. There were 10 animals/group. Results are shown as
mean SD. *P<0.01.
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The mechanism through which IL-6 contributes to
overall prostate tumor growth is not clear. There are
con¯icting reports regarding the effect of IL-6 on
prostate cancer cell proliferation in vitro [4]. Thus, it is
unclear if IL-6 directly contribute to tumor growth
through stimulation of cell proliferation. In addition to
increased cell proliferation, a tumor may enlarge due
to decreased apoptotic death of cell. The observation
that IL-6 has been demonstrated to have anti-apoptotic
action in several cell types [19,25,26] including the
prostate cancer cell lines LNCaP and PC-3 (27) led us
to evaluate IL-6's effect on apoptosis in the prostate
cancer xenografts. Our observation that the level of
apoptosis in tumors of mice that received anti-IL-6
compared to those who received isotype control anti-
body demonstrates that IL-6 protects prostate cancer
cells from apoptosis in vivo. These ®ndings are
consistent with the in vitro results of Chung et al.
[27] who demonstrated the antiapoptotic effects of IL-6
in PC-3 and LNCaP cell lines, and showed that this
effect is the result of IL-6 activation of phosphatidy-
linositol (PI)-3 kinase. These previous reports, taken
together with the currently reported murine studies,
suggest that inhibition of apoptosis is one mechanism
through which IL-6 contributes to prostate cancer
progression.
CONCLUSION
In summary, the current study demonstrates that
anti-IL-6 antibody induces apoptosis and regression of
established PC-3 tumors in mice. However, the in vivo
Fig. 4. Inhibition of IL-6 induces apoptosis in PC-3 tumors inmice.Tumorswere excised frommice 4 weeks after initiation of anti-IL6 and
etoposide as describedin Fig. 3.Breaks inDNAwere determinedby labeling 3 0OHterminiusing terminal deoxytransferase and stainingwith
peroxidase.Tumor sections are shown from(A) isotype-treatedmice and (B) anti-IL-6 treatedmice.Apoptotic nuclei are darkbrown (arrow-
heads).Originalmagnification100 .C:To determine the degree of apoptosis, the number of apoptotic nuclei/200 field (average of tripli-
cate) were determinedby an investigator blinded to the samples. *P<0.01compared to the saline isotypemice; *P<0.05 compared to the
etoposide isotypemice.Data are shown asmean SD of 4mice/group.
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data do not support the in vitro observations that IL-6
enhances etoposide-mediated killing. These data, com-
bined with the clinical reports that IL-6 is associated
with prostate cancer stage [17,18,28], provide compel-
ling evidence that IL-6 contributes to prostate cancer
progression and suggests that targeting IL-6 may
induce prostate cancer regression.
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